Vigilant Capital Management’s GSK GSK Stock Holding History

Vigilant Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,140	Closed	-$34K	–	527
2022 Q3	$34K	Buy	+1,140	New	+$43.2K	﹤0.01%	330
2022 Q2	–	Sell	-800	Closed	-$44K	–	601
2022 Q1	$44K	Buy	+800	New	+$43.5K	﹤0.01%	312
2021 Q4	–	Sell	-233	Closed	-$11K	–	681
2021 Q3	$11K	Buy	233 +114	+96%	+$5.73K	﹤0.01%	473
2021 Q2	$6K	Hold	119	–	–	﹤0.01%	387
2021 Q1	$5K	Buy	+119	New	+$5.4K	﹤0.01%	340
2020 Q1	–	Sell	-560	Closed	-$33K	–	365
2019 Q4	$33K	Buy	+560	New	+$31.1K	﹤0.01%	350
2019 Q3	–	Sell	-2,000	Closed	-$100K	–	388
2019 Q2	$100K	Sell	2,000 -9,578	-83%	-$481K	0.01%	178
2019 Q1	$605K	Buy	11,578 +1,924	+20%	+$96.1K	0.08%	70
2018 Q4	$461K	Buy	9,654 +2,182	+29%	+$107K	0.07%	79
2018 Q3	$375K	Hold	7,472	–	–	0.05%	95
2018 Q2	$376K	Hold	7,472	–	–	0.05%	89
2018 Q1	$365K	Hold	7,472	–	–	0.05%	92
2017 Q4	$331K	Buy	+7,472	New	+$345K	0.04%	102

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vigilant Capital Management's GSK Position: Q4 2022 in Review

Vigilant Capital Management sold out of GSK (GSK) in Q4 2022, closing a stake of 1,140 shares — an estimated $34K sold.

Vigilant Capital Management first reported a position in GSK in Q4 2017 and held it in 13 quarters. The position peaked at $605K in Q1 2019. 813 funds tracked by Wall St. Rank hold GSK as of Q4 2022.

Vigilant Capital Management reported no remaining GSK position as of Q4 2022 after selling out during the quarter.
Vigilant Capital Management sold 1,140 GSK shares in Q4 2022, an estimated $34K.
Vigilant Capital Management first reported a position in GSK in Q4 2017 and held it in 13 quarters.
Vigilant Capital Management's GSK position peaked at $605K in Q1 2019.
813 funds tracked by Wall St. Rank held GSK as of Q4 2022.

Based on Vigilant Capital Management's 13F filing for Q4 2022, filed 26 Jan 2023.